Xgeva Delays Bone Complications in Women with Metastatic Breast Cancer

In a study of women with bone metastases from breast cancer, Xgeva™ (denosumab) delayed bone complications for five months longer than Zometa® (zoledronic acid). These updated results from a Phase III clinical trial were presented at the 2010 San Antonio …

Source: Breast Cancer News

Leave a Reply

Your email address will not be published. Required fields are marked *